NCT06846671 2026-04-16
CaDAnCe-302
BeOne Medicines
Phase 3 Recruiting
Clinical Trials
49 trialsNCT06943872 2026-04-15
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
BeOne Medicines
Phase 3 Recruiting
NCT01886872 2026-04-13
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT07139873 2026-03-27
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Dizal Pharmaceuticals
Phase 3 Recruiting
NCT05624554 2026-03-16
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05947851 2026-03-13
BELLWAVE-010
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT03336333 2026-03-09
SEQUOIA
BeOne Medicines
Phase 3 Active not recruiting
NCT04075292 2026-03-05
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
AstraZeneca
Phase 3 Active not recruiting
NCT04285567 2026-03-03
CRISTALLO
Hoffmann-La Roche
Phase 3 Completed
NCT02970318 2026-02-06
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Acerta Pharma BV
Phase 3 Active not recruiting
NCT04965493 2026-01-29
BRUIN CLL-322
Eli Lilly and Company
Phase 3 Active not recruiting
NCT05023980 2026-01-22
BRUIN CLL-313
Eli Lilly and Company
Phase 3 Active not recruiting
NCT06970743 2026-01-07
CaDAnCe-303
BeOne Medicines
Phase 3 Recruiting
NCT02048813 2025-11-28
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04666038 2025-04-20
BRUIN CLL-321
Eli Lilly and Company
Phase 3 Active not recruiting
NCT00769522 2024-12-31
FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia
German CLL Study Group
Phase 3 Completed
NCT02950051 2024-12-30
GAIA
German CLL Study Group
Phase 3 Completed
NCT00004112 2024-09-23
Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
University of Nebraska
Phase 3 Completed
NCT03078855 2024-09-04
ILyAD
University of Rochester
Phase 3 Completed
NCT00877214 2024-08-22
MAINTAIN
University of Giessen
Phase 3 Active not recruiting
NCT00991211 2024-08-22
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab
University of Giessen
Phase 3 Completed
NCT06205290 2024-04-02
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Withdrawn
NCT00075946 2024-02-01
Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT02005471 2023-10-17
MURANO
Hoffmann-La Roche
Phase 3 Completed
NCT04578613 2023-06-05
ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3 Unknown
NCT02576275 2021-03-17
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
SecuraBio
Phase 3 Withdrawn
NCT00551239 2020-10-19
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
CTI BioPharma
Phase 3 Withdrawn
NCT00513747 2020-04-22
Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT01569295 2020-03-10
Tugela
Gilead Sciences
Phase 3 Completed
NCT01611090 2020-03-03
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Janssen Research & Development, LLC
Phase 3 Completed
NCT01118234 2020-01-09
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 3 Completed
NCT00275054 2019-05-23
Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia
German CLL Study Group
Phase 3 Completed
NCT01539512 2019-05-14
A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Gilead Sciences
Phase 3 Completed
NCT01980888 2018-11-19
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 3 Terminated
NCT01732913 2018-11-16
Yosemite
Gilead Sciences
Phase 3 Terminated
NCT01732926 2018-11-16
Bridalveil
Gilead Sciences
Phase 3 Terminated
NCT01010061 2018-09-14
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)
Hoffmann-La Roche
Phase 3 Completed
NCT01998880 2018-09-14
CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)
Hoffmann-La Roche
Phase 3 Completed
NCT02053610 2018-09-14
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)
Hoffmann-La Roche
Phase 3 Completed
NCT00718549 2018-08-20
A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)
Hoffmann-La Roche
Phase 3 Completed
NCT01973387 2018-07-24
A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma
Janssen Research & Development, LLC
Phase 3 Completed
NCT00090051 2017-08-01
FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients
Hoffmann-La Roche
Phase 3 Completed
NCT00645606 2017-08-01
LLC2007SA
University Hospital, Tours
Phase 3 Completed
NCT00801281 2017-07-17
PLRG4
Polish Lymphoma Research Group
Phase 3 Completed
NCT00254163 2016-11-03
Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients
US Oncology Research
Phase 3 Completed
NCT00281918 2013-09-19
CLL-8
Hoffmann-La Roche
Phase 3 Completed
NCT00564512 2013-07-25
Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP
French Innovative Leukemia Organisation
Phase 3 Completed
NCT00003204 2013-02-27
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT01670812 2012-08-22
Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia
The First Affiliated Hospital with Nanjing Medical University
Phase 3 Unknown